Radiology Business April 2, 2025
Drugmaker Lantheus has completed its acquisition of radiopharmaceutical firm Evergreen Theragnostics in a deal valued at up to $1 billion.
The North Billerica, Massachusetts-based buyer announced the deal’s closing on Tuesday after scoring the necessary regulatory approvals. Founded in 2019 and headquartered in Springfield, New Jersey, Evergreen develops and manufactures imaging agents for diagnosing and treating cancer. Its portfolio includes Octevy, a yet-to-be-approved PET (positron emission tomography) product targeting neuroendocrine tumors.
Lantheus believes the imaging agent will complement its therapeutic PNT2003—a generic version of Lutathera for treating such cancers—and solidify its status as a “fully integrated radiopharmaceutical company.”
“By acquiring Evergreen Theragnostics, we are enhancing Lantheus’ capabilities across the entire radiopharmaceutical value chain, from development to manufacturing to commercialization,”...
Today's Sponsors
Today's Sponsor